Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital

References

• Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts. Curr Drug Targets 2006; 7: 495–504.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133–163.
   PubMed Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128–140.
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685–702.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10: 11–23.
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52: 71–77.
   PubMed Web of Science ®Google Scholar
• Wu CJ, Lee HC, Lee NY, . Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan,1996–2003. J Microbiol Immunol Infect 2006; 39: 135–143.
   PubMedGoogle Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309–317.
   PubMed Web of Science ®Google Scholar
• Chai YA, Wang Y, Khoo AL, . Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. Med Mycol 2007; 45: 435–439.
   PubMed Web of Science ®Google Scholar
• Xess I, Jain N, Hasan F, Mandal P, Banerjee U. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 2007; 35: 256–259.
   PubMed Web of Science ®Google Scholar
• Tan TY, Tan AL, Tee NW, Ng LS, Chee CW. The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study. Mycoses 2010; 53: 515–521.
   PubMed Web of Science ®Google Scholar
• Choi HK, Jeong SJ, Lee HS, . Blood stream infections by Candida glabrata and Candida krusei: a single-center experience. Korean J Intern Med 2009; 24: 263–268.
   PubMedGoogle Scholar
• Anunnatsiri S, Chetchotisakd P, Mootsikapun P. Fungemia in non-HIV-infected patients: a five-year review. Int J Infect Dis 2009; 13: 90–96.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 2006; 12: 132–138.
   PubMedGoogle Scholar
• Holley A, Dulhunty J, Blot S, . Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009; 33: 554, e1–554, e7.
   Google Scholar
• Cheng MF, Yang YL, Yao TJ, . Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005; 5: 22–26.
   PubMedGoogle Scholar
• Chow JK, Golan Y, Ruthazer R, . Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008, 36: 1993–1998.
   PubMed Web of Science ®Google Scholar
• Lin MY, Carmeli Y, Zumsteg J, . Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555–4560.
   PubMed Web of Science ®Google Scholar
• Playford EG, Marriott D, Nguyen Q, . Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034–2039.
   PubMed Web of Science ®Google Scholar
• Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873–878.
   PubMed Web of Science ®Google Scholar
• Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007; 41: 568–573.
   PubMed Web of Science ®Google Scholar
• Munoz P, Sanchez-Somolinos M, Alcala L, . Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005; 55: 188–193.
   PubMed Web of Science ®Google Scholar